Non-invasive Screening and Detection of Cervical Cancer

Double Blinded Clinical Study for Screening and Detection of Cervical Cancer Using Fluorescence and Diffuse Reflectance Imaging - CERVISCAN

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2021/02/030885

Enrollment

110

Registered

2021-02-01

Start date

Unknown

Completion date

Unknown

Last updated

2024-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N879- Dysplasia of cervix uteri, unspecified Health Condition 2: N72- Inflammatory disease of cervix uteri Health Condition 3: N870- Mild cervical dysplasia Health Condition 4: N871- Moderate cervical dysplasia

Interventions

Intervention1: CERVICAL IMAGING: The patient cervix is imaged using a multispectral imaging camera (Cerviscan) on exposure of the cervix with a speculum Control Intervention1: Pap Smear: After imaging

Eligibility

Inclusion criteria

Inclusion criteria: 1 Patients referred for Pap smear test 2 Patients with any kind of clinically suspected lesions in the uterine cervix

Exclusion criteria

Exclusion criteria: 1 Patients who had undergone previously treatments for cancer 2 Patients with transmittable diseases

Design outcomes

Primary

Measure	Time frame
1. Patient will have the possibility to get a more precise/accurate screening for cervical cancer using Cerviscan 2. Location of most malignant site for biopsy using Cerviscan helps to minimize false negative and unnecessary biopsiesTimepoint: 1 week	—

Secondary

Measure	Time frame
Identification of areas of tissue inflammationTimepoint: 1 week	—

Countries

India

Contacts

Public ContactDr Subhash Narayanan

Sascan Meditech Pvt Ltd

subhash.sascan@gmail.com9591345016

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026